Cambridge Investment Research Advisors’s Galmed Pharmaceuticals GLMD Stock Holding History

Cambridge Investment Research Advisors’s Portfolio GLMD Stock Details GLMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-1,267	Closed	-$19K	–	3768
2025 Q2	$19K	Buy	+1,267	New	+$14.9K	﹤0.01%	3581
2023 Q2	–	Sell	-20	Closed	-$12K	–	3226
2023 Q1	$12K	Hold	20	–	–	﹤0.01%	3128
2022 Q4	$14K	Sell	20 -4	-17%	-$2.1K	﹤0.01%	3069
2022 Q3	$11K	Buy	24 +5	+26%	+$3.41K	﹤0.01%	3021
2022 Q2	$18K	Buy	19 +1	+6%	+$1.33K	﹤0.01%	3005
2022 Q1	$42K	Buy	+18	New	+$40.8K	﹤0.01%	3088

Other funds holding GLMD

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

WANY

Wealthspire Advisors (New York) New York $18.2B AUM 21.48% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

FDCDDQ

Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $32.7B AUM 35.71% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

Allworth Financial Folsom, California $23.6B AUM 20.99% 1-Year Est. Return

Cambridge Investment Research Advisors's GLMD Position: Q3 2025 in Review

Cambridge Investment Research Advisors sold out of Galmed Pharmaceuticals (GLMD) in Q3 2025, closing a stake of 1,267 shares — an estimated $19K sold.

Cambridge Investment Research Advisors first reported a position in GLMD in Q1 2022 and held it in 6 quarters. The position peaked at $42K in Q1 2022. 10 funds tracked by Wall St. Rank hold GLMD as of Q3 2025.

Cambridge Investment Research Advisors reported no remaining Galmed Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
Cambridge Investment Research Advisors sold 1,267 Galmed Pharmaceuticals shares in Q3 2025, an estimated $19K.
Cambridge Investment Research Advisors first reported a position in Galmed Pharmaceuticals in Q1 2022 and held it in 6 quarters.
Cambridge Investment Research Advisors's Galmed Pharmaceuticals position peaked at $42K in Q1 2022.
10 funds tracked by Wall St. Rank held Galmed Pharmaceuticals as of Q3 2025.

Based on Cambridge Investment Research Advisors's 13F filing for Q3 2025, filed 12 Nov 2025.